Introduction 31
Overcoming treatment resistance is a major goal of cancer research. Various cell types within 32 the tumor microenvironment (TME) have been posited as barriers to effective treatment including 33 macrophages(1, 2), monocytes(3), fibroblasts(4), neutrophils(5), regulatory T-cells(6), and endothelial of downstream STAT proteins. Untreated, KLM-1 cells showed activation of both STAT1 and 152 STAT3, whereas tofacitinib treatment eliminated detectable P-STAT3 (Supplementary Figure 2G) . 153 STAT1 activation was impacted only moderately. Similar results were obtained for MDA-MB-468 154 cells, which showed a robust P-STAT3 signal, consistent with the constitutive activation of STAT3 155 in many breast cancers (48) (Supplementary Figure 2H) . Tofacitinib treatment completely 156 abrogated P-STAT3, but did not alter STAT1 phosphorylation. Our results confirmed that 157 tofacitinib inhibited the phosphorylation of relevant downstream JAK effectors in both cell lines 158 and that failure to enhance immunotoxin action in tissue culture was unrelated to drug resistance or 159 aberrant signaling pathways. 160 Tofacitinib treatment enhances tumor uptake of antibody-based agents 161 As tofacitinib enhanced the anti-tumor activity of immunotoxins in vivo, but displayed no 162 single agent activity and no enhancement in vitro, we considered that tofacitinib was altering the 163 tumor microenvironment, either permitting increased immunotoxin access to tumor cells or altering 164 survival or proliferation signals. To examine the first possibility, we quantified the delivery of 165 fluorescently-labeled immunotoxin to tumor cells in xenograft models. Tumor-bearing mice were 166 pre-treated for ~70 hours with either vehicle or tofacitinib and then administered fluorescently-167 labeled immunotoxin. Based on immunotoxin half-life and prior studies examining tumor 168 uptake(49), tumors were excised 3 hours post-injection, enzymatically dissociated into single-cell 169 suspensions and analyzed for immunotoxin uptake by flow cytometry (Supplementary Figure 3A) . 170 Tumor cells were identified via gating with a human-specific anti-EGFR antibody to ensure that 171 only uptake into malignant cells was analyzed.
172
When KLM-1 tumors were retrieved from mice injected with fluorescently labeled LMB-100 173 (LMB-100-Alexa647), the average (n=4 independent experiments) labeling of recovered malignant 174 cells approached a median of 29% at 3 hours post-injection. However, when mice were pretreated 175 with tofacitinib, 43% of malignant cells exhibited an immunotoxin signal (Figure 2A) (*, p=0.04). 176 Similarly, mice bearing MDA-MB-468 tumors and treated with Alexa647-labeled HB21-PE40 for 3 177 hours showed increased tumor cell uptake of labeled immunotoxin in mice pretreated with 178 tofacitinib compared to mice treated with vehicle ( Figure 2B ) (p=0.05). These results confirmed a 179 tofacitinib-mediated increase in the delivery of immunotoxin to tumor cells and suggested a 180 potential explanation for the enhancement of immunotoxin activity. 181 To determine if tofacitinib-mediated enhancement of delivery was applicable to other 182 antibody-based therapeutics, tumor uptake of a fluorescently labeled full-length antibody was 183 investigated. TNBCs often overexpress the epidermal growth factor receptor (EGFR) and up to 184 90% of PDACs show EGFR overexpression. Therefore, mice with KLM-1 (Figure 2C) or MDA-185 MB-468 ( Figure 2D) xenografts were injected with a fluorescently labeled anti-EGFR monoclonal 186 antibody following tofacitinib or vehicle pretreatment. With vehicle-treated mice, a median of 13% 187 of KLM-1 tumor cells, identified with an antibody to the human transferrin receptor (TfnR), were 188 associated with a positive anti-EGFR-BV421 signal. However, with tofacitinib pretreatment 20% of 189 tumor cells showed positive signal (p=0.004). Similarly, MDA-MB-468 tumors showed an increase 190 in antibody uptake when treated with both anti-EGFR and tofacitinib compared to tumors treated 191 with anti-EGFR plus vehicle (9.3% to 4.0%; p=0.04). Like the uptake of immunotoxins, tumors 192 from mice receiving tofacitinib treatment showed a 1.5-2-fold increase in the number of cells experiments with lower anetumab ravtansine dosing showed similar trends of enhancement, albeit 208 with lower magnitude effects ( Supplementary Fig 4A, B,C and D) , confirming a tofacitinib-209 mediated enhanced delivery of this therapeutic. Thus, pretreatments of tumor-bearing mice with 210 tofacitinib had the general effect of enhancing antibody-mediated anti-tumor efficacy, suggesting the 211 existence of treatment barriers that limit the effectiveness of antibody-based therapeutics.
212

Tofacitinib-mediated downregulation of inflammatory cytokine and arginase expression 213
Tofacitinib did not enhance immunotoxin activity in tissue culture, but enhanced therapeutic 214 uptake in vivo, suggesting action at the level of the tumor itself. To determine if tofacitinib 215 inhibition of JAK-STAT signaling could alter the TME transcriptome, RNA was isolated from 216 KLM-1 tumors that had received no treatment, vehicle alone, or tofacitinib. Transcript profiles for 217 murine immune-related genes were then evaluated by Nanostring technology. Transcript counts 218 similar between vehicle and untreated tumors, but altered in tofacitinib-treated tumors were 219 identified by agglomerative clustering analysis (Supplementary Figure 5) . Differential expression 220 of this subset of genes was then determined for vehicle-and tofacitinib-treated tumors, and genes 221 with at least two-fold downregulation identified (Table 1) . Tofacitinib-downregulated transcripts 222 could be broadly grouped into three functional categories: neutrophil/granulocyte chemokines, 223 monocyte chemokines, and B-cell activation proteins. The transcripts showing the greatest 224 reductions in tofacitinib-treated tumors were neutrophil chemokines Cxcl2 (-7.46-fold) and Cxcl3 (-225 6.29-fold), with monocyte chemokines (Ccl4, -3.62; Ccl1, -3.35, Ccl3, -2.86) and B-cell activation 226 pathway components (Pax5, -3.78; Il13, -2.48) also reduced ( Table 1) . Transcripts for arginase-1 (-227 2.37) and COX2 (-1.58), which are often highly expressed in MDSCs and suppress anti-tumor 228 immune activity were also downregulated. Fewer genes were upregulated in tofacitinib-treated KLM-229 1 tumors compared to vehicle/untreated tumors ( Table 2) . The most differentially expressed gene 230 was interferon alpha (+3.85-fold), an anti-viral cytokine which stimulates Natural Killer (NK) cell 231 cytotoxic activity upon STAT1 inhibition(50). However, genes upregulated by tofacitinib treatment 232 did not obviously cluster into functional groupings and were not studied further.
233
Nanostring analysis revealed that tofacitinib treatment showed the largest effect on indicating that the tumor had stimulated production ( Figure 4A) . Treatment with tofacitinib 241 significantly reduced serum levels of both chemokines, decreasing CXCL2 to 25.1 pg/ml, only a 1.6-242 fold increase over naïve mice (p<0.001). Circulating CCL4 was similarly reduced, from 38.4pg/ml in 243 vehicle-treated tumors to 8.4pg/ml in tofacitinib-treated mice (p=0.02). Naive mice showed slightly 244 higher levels of CCL2 compared to the other chemokines (30.6 pg/ml); however, in mice bearing 245 KLM-1 tumors, circulating CCL2 doubled to 61pg/ml. Treatment with tofacitinib reduced this 246 expression to 38.9pg/ml (p=0.004). Mice bearing KLM-1 tumors showed a minimal increase in IL6 247 over naïve mice (33.6 to 38.1pg/ml), which was abrogated in tofacitinib-treated mice (32.7pg/ml) 248 ( Figure 4B) . However, mice with MDA-MB-468 tumors showed a tripling of circulating IL6 249 compared to naïve mice (33.6 to 87.1pg/ml) consistent with the role that IL6 plays in TNBC growth 250 and metastasis. Treatment with tofacitinib resulted in a significant decrease in IL6, to levels 251 comparable to naïve mice (32.8pg/ml) (p=0.01). These data confirmed that tofacitinib reduced key 252 cytokines associated with inflammatory cell recruitment and tumorigenesis.
253
The presence of tumor-associated neutrophils, MDSC, and tumor-associated macrophages is 254 linked frequently to a tumor-permissive environment through release of pro-inflammatory cytokines 255 and production of immune suppressing molecules like arginase-1 or cyclooxygenase 2 (COX-2)(52-256 54). As arginase expression is regulated by STAT signaling(55) and showed more than 2-fold 257 downregulation of transcript level upon tofacitinib treatment (Table 1) , changes in arginase activity 258 levels within tumors were also examined. The enzymatic activity of arginase-1 in tumor supernatants 259 was measured through the conversion of L-arginine to urea(56). Tofacitinib treatment of KLM-1 260 xenografts showed an approximately 20% reduction in tumor-associated arginase activity compared 261 to vehicle-treated tumors (p=0.02) ( Figure 4C) . Treatment of MDA-MB-468 xenografts with 262 tofacitinib showed a similar trend, significantly reducing tumor-associated arginase enzymatic activity 263 to 43% of vehicle-treated tumors (p=0.03)( Figure 4C ). Taken together, these data suggested that 264 tofacitinib alters the TME by reducing the recruitment and/or activity of certain immune 265 populations.
267
Tofacitinib reduces recruitment of tumor-associated neutrophils, macrophages, and myeloid cells 268 To determine whether tofacitinib treatment altered the composition of the tumor, 269 immunohistochemistry (IHC) was performed on xenografts treated with immunotoxin, tofacitinib, 270 or the combination (Figure 5A) . Given the depletion of myeloid cell and neutrophil chemotactic 271 proteins, antibodies reactive for markers of myeloid cells (α-CD11b or α-GR-1), neutrophils (α-272 myeloperoxidase (MPO) or α -LY6G), or murine macrophages (α-F4/80) were utilized to determine 273 if these inflammatory cell populations within the tumor were altered by tofacitinib treatment. Images 274 were captured for each treatment group and scored for the presence and quantity of each cell 275 marker from at least 20 random fields for each treatment. In KLM-1 tumors, TAMs were obviously 276 depleted in tofacitinib-treated animals compared to vehicle-treated tumors (Figure 5A) . Vehicle-277 treated tumors showed a median of 42 F4/80 + cells per field (range: 7-140), which was significantly 278 reduced in tofacitinib-treated animals to 18 cells/field (6-88) (p<0.01). Tumor-associated CD11b + 279 myeloid cells also decreased in response to tofacitinib treatment (Figure 5B) . Vehicle-treated 280 tumors showed CD11b + cells scattered throughout the tumor stroma, while these cells were barely 281 detectable in tofacitinib treated tumors. Vehicle-treated tumors scored a median of 20 CD11b + cells 282 per field (range: 3-45), while treatment with tofacitinib significantly reduced this number to 1 283 cell/field (0-8) (p<0.001). Similarly, vehicle-treated tumors showed MPO + cells (arrowheads) within 284 the stroma, but also among the tumor cells ( Figure 5C ). The population of MPO + cells was also 285 altered significantly in tofacitinib-treated tumors, as MPO + cells decreased by ~80% compared to 286 vehicle, from a median of 20 MPO + cells/field of view (range: 2-88) to 3 MPO + cells per field (0-47) 287 (p<0.001) ( Figure 5C ). Finally, to confirm that tumor-associated neutrophils were depleted by 288 tofacitinib, a second granulocyte marker, LY6G, was examined ( Figure 5D ). Vehicle-treated tumors 289 showed a median of 17 LY6G + cells/field of view (range: 0-104), again in both the tumor stroma 290 and among the malignant cells. Tofacitinib significantly reduced LY6G + cells to a median of merely 291 1/field (0-41).
292
Similar trends were noted for IHC staining of inflammatory cell populations in MDA-MB-293 468 tumors (Supplementary Figure 6A) , although there were fewer inflammatory cells overall.
294
Tofacitinib-treatment modestly, but significantly, reduced median CD11b + cells compared to vehicle 295 from 9 (range: 0-60) to 4 (0-28) ( Supplementary Figure 6B ; p=0.009). As the CD11b + staining in 296 MDA-MB-468 tumors was less well defined than in KLM-1 tumors, we also identified myeloid cells 297 using the GR1-LY6G marker. Tofacitinib similarly resulted in a moderate reduction in tumor-298 associated GR1-LY6G + cells from a median of 16 cells/field (range: 5-46) to 12 (0-32) (p=0.04) 299 (Supplementary Figure 6C) . Finally, tofacitinib depleted MPO + cells in MDA-MB-468 tumors 300 (Supplementary Figure 6D) . Vehicle-treated tumors showed a median of 18 MPO + cells/field 301 (range: 0-41), while tofacitinib-treated tumors only had 8 MPO + cells/field (0-46) (p=0.04). In the 302 above experiments, tumors were harvested 3 days after receiving the first injection of tofacitinib and 303 then scored for the presence of short-lived inflammatory cells: neutrophils (typical T 1/2 of less than 304 a day), monocytes (a T 1/2 of 1-2 days), and TAMs, which are substantially lowered after 3 days 305 treatment with other macrophage depleting agents. Our data confirm that short duration treatments 306 can result in tofacitinib-mediated depletion of chemokine levels and reduced recruitment of 307 inflammatory cells into the TME. (Supplementary Figure 7A ). Similar to results in the xenograft models, tumor-317 associated inflammatory cells were reduced following tofacitinib treatment, with significant 318 decreases noted in the number of CD11b + cells (p=0.04), MPO + cells (p<0.001), LY6G + 319 granulocytes (p<0.001), and F4/80 + macrophages (p=0.002). However, as seen in both xenograft 320 tumor models, no significant differences in tumor growth rate were recorded with tofacitinib 321 treatments, suggesting that anti-tumor cell functions that otherwise might be keeping the tumor in-322 check were not significantly compromised under these short duration treatment regimens. Figure 7E) . Arginase enzymatic activity within the syngeneic 4T-1 breast cancer 324 tumors were also measured as before, with tofacitinib treatment reducing tumor-associated arginase 325 activity to 68% of vehicle-treated tumors (Supplementary Figure 7F ; p<0.001).
323
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Non-target updake of immunotoxins by tumor-associated inflammatory cells 328 The reduction in tumor-associated inflammatory cells following tofacitinib treatments 329 coupled with enhanced uptake of antibodies into malignant cells suggested that inflammatory cells 330 could be altering therapeutic protein availability. To address this, we first investigated whether 331 tofacitinib altered the pharmacokinetics of immunotoxin metabolism. Sera from mice bearing KLM-332 1 tumors pre-treated with tofacitinib or vehicle were harvested at 0, 15, 30, 45, and 60 minutes post-333 injection and assayed for LMB-100 immunotoxin levels by ELISA ( Figure 6A ). Mice treated with 334 vehicle had an immunotoxin half-life of 25 minutes, similar to previous reports (57), while mice 335 treated with tofacitinib had a half-life of 46 minutes (p=0.02). Tofacitinib additionally increased the 336 immunotoxin exposure (area under curve from t=0 to t=60) by 35%, suggesting that malignant cells 337 had a greater exposure to immunotoxin molecules. Likewise, drug levels for the immunotoxin, by the presence of a malignancy, or on inflammatory cells in general, a similar experiment was 345 performed in naïve mice. As before, sera from mice pre-treated with tofacitinib or vehicle and 346 injected with LMB-100 were harvested at 0, 15, 30, 45, and 60 minutes post-injection and assayed 347 for LMB-100 immunotoxin levels by ELISA ( Figure 6B) . Naïve mice showed an LMB-100 half-life 348 of 23 minutes, while tofacitinib-treated mice had an increased half-life of 32 minutes (p=0.66).
349
Treatment with tofacitinib increased immunotoxin exposure by almost one-third compared to 350 vehicle-treated mice, suggesting that tofacitininb may be acting more generally and not just on (Figure 6C) . 364 Almost two-thirds of immunotoxin-positive cells in vehicle-treated tumors were mCD11b + 365 suggesting that the majority of immunotoxin uptake was associated with off-target inflammatory cell 366 populations (Figure 6C) . Tofacitinib-treated tumors still showed a majority of immunotoxin within 367 mCD11b + cells; however, this population was significantly reduced compared to vehicle-treated 368 tumors (55%; p=0.007). When this population was further divided into mCD11b + /mCD68 + 369 macrophage and mCD11b + /mLY6G + granulocyte populations, tofacitinib-treated tumors showed a 370 one-third reduction in macrophage-associated LMB-100-A647 (p=0.05), but only a minimal 371 reduction in granulocyte-associated immunotoxin (Figure 6D) . Concurrent with the reduction in 372 mCD11b + /LMB100-A647 + cells in tofacitinib-treated tumors, was an increase in 373 huEGFR + /LMB100-A647 + cells compared to vehicle-treated tumors (tofacitinib: 34% vs 22% 374 vehicle; p<0.001).
375
In tumor-bearing animals, inflammation is not confined to the tumor microenvironment 376 but also noted in the spleen, a significant source of precursor inflammatory cells which transit to the 377 tumor, differentiate into TAM/TAN, and accumulate within the tumor(58, 59). Therefore we 378 examined spleens from tumor-bearing mice with and without tofacitinib treatment. In mice bearing 379 KLM-1 tumors, we noted a 25% increase in spleen weight (0.22g ± 0.02g, n=4) compared to naïve 380 mice (0.16g ± 0.01g, n=2). In contrast, spleens from tumor-bearing mice receiving tofacitinib 381 showed only 10% increase in weight (0.18g ± 0.01g, n=4) over naïve mice, suggesting a drug-382 mediated reduction in splenic inflammation, consistent with published reports(60). Further, when 383 splenocytes from naïve and tumor-bearing mice were analyzed by flow cytometry, tofacitinib 384 treatment resulted in a 10% reduction in overall CD11b + populations and a 20% reduction in 385 CD68 + populations ( Supplementary Fig 8B and C) . Thus it is likely that short duration tofacitinib 386 treatments reduce potential non-target sinks for antibody-based agents not only at the tumor site, Previously, we reported that the generation of anti-immunotoxin antibodies in 395 immunocompetent mice was inhibited by tofacitinib, reducing titers by more than 200-fold(41).
396
Here we extend those findings and report on a second substantial benefit of using tofacitinib, tumors and decreased non-target uptake of immunotoxin by inflammatory cells was not anticipated. 408 Our data suggests that depletion of these cell types may explain the in vivo enhancement of 409 antibody-based therapeutics in several xenograft models.
410
The chronic inflammatory state associated with many cancers often results in the 411 accumulation of innate immune cells associated with wound healing and repair, which respond to 412 cytokines released by the tumor and in turn, release growth factors, angiogenic factors, and cytokines 413 that promote tumor growth, metastases and immune suppression(61). This polarization of the 414 tumor environment towards an "alternative" state is predicated on cytokine crosstalk between tumor 415 cells, stroma, and the host immune system, suggesting that targeting common signaling pathways 416 could disrupt a pro-tumorigenic environment (24, 62, 63). Intriguingly, a recent article reported on 417 systemic inflammation with monocyte and neutrophil mobilization that could be abolished by a few 418 treatments with anti-inflammatory agents(64). In our study, histological examination of tumor 419 inflammatory cell populations confirmed that TAM and TAN populations were depleted in 420 tofacitinib-treated tumors. Published reports indicate that the proliferation of TAMs within the 421 tumor microenvironment is diminished compared to counterparts in normal tissue; similarly, 422 neutrophils are short-lived cells and rapidly undergo apoptotic cell death, so both inflammatory 423 populations must be continuously recruited to tumors via chemotactic pathways(2). Accumulation 424 of TAMs is an independent predictor of poor patient outcomes in many cancer types, including 425 breast and pancreatic cancers, and are associated with increased resistance to therapeutics(65, 66).
426
Additional depletion of neutrophils in a cancer setting may play a beneficial role as TANs are 427 associated with disease progression and poor outcomes in many cancers (67) (68) (69) . Similarly, the 428 modulation of tumor-supporting immune cell populations has been recently identified as a 429 significant component in the effectiveness of cancer treatments with antibodies against immune 430 checkpoint proteins PD-1/PD-L1(70), and CTLA-4(71).
431
Reductions in inflammatory cells after tofacitinib treatment in the 4T-1 syngeneic breast 432 cancer model confirmed that our findings were not peculiar to human xenografts or athymic nude 433 mice. In fact, short-term treatments with tofacitinib achieved qualitative effects similar to other 434 agents designed to inhibit macrophage or monocyte recruitment to tumors, such as novelizumab, 435 carlumab, or RG7155(2). In PDAC and other tumor models, various anti-macrophage treatments 436 have increased the susceptibility of malignant cells to either chemotherapy or checkpoint 437 inhibitors(72-74), and the use of anti-inflammatory drugs in combination with the standard of care 438 in breast(75) and pancreatic(76) cancers has shown some promise. In addition to these 439 combinations, we propose a novel use for agents that inhibit the recruitment of inflammatory cells, 440 namely the increased bioavailability and enhanced uptake of antibodies into malignant cells. In 441 support of this, we report substantial non-target uptake of immunotoxins by inflammatory cells in 442 tumor-bearing mice. Due to the short half-lives of recombinant immunotoxins, uptake was 443 measured 3 hours after injection. Results indicated that at this time point, a majority of tumor-444 associated immunotoxin was recovered within inflammatory cells in vehicle-treated mice. In 445 tofacitinib treated mice, there were fewer inflammatory cells containing immunotoxin, and thus we 446 speculate that decreased non-target uptake leads to increased on-target delivery to malignant cells.
447
While these experiments provided a quantitative insight into the short-term fate of immunotoxins, 448 long-term effects were also evident, seen in the enhanced anti-tumor activity observed with three 449 unique antibody-based therapeutic agents. immunotherapies has proven significantly more effective than immunotherapy or gemcitabine alone, 455 suggesting that depletion of MDSC or neutrophil populations may be a general mechanism to 456 improve patient outcomes(80). Revelant to our study, treatment with gemcitabine in conjunction 457 with immunotoxin resulted in better tumor clearance in vivo than either agent alone, while having 458 no enhancement effect in vitro(81). These studies suggest that compounds that inhibit the 459 expansion or recruitment of immunosuppressive and tumor-promoting immune populations may 460 prove effective at enhancing antibody-based therapies. However, it remains difficult to identify 461 these agents using in vitro screening because contributions of the tumor microenvironment are 462 difficult to duplicate outside the intact animal.
463
Previous efforts for improving drug delivery were primarily predicated upon two different 464 approaches: normalization of the vasculature through anti-angiogenesis agents, or depletion of ECM 465 and tumor stromal cells(82). However, recent focus has shifted to reducing the inflammatory state of 466 the tumor itself to stimulate vascular normalization, reduce edema, and deplete pro-tumorigenic 467 inflammatory cells (7). While our study provides evidence that reducing tumor inflammation may 468 enhance the efficacy of tumor-directed antibodies, it has not revealed whether increased antibody 469 delivery reflects only relief from non-specific uptake by inflammatory cells or if other mechanisms 470 are operative. We have yet to examine whether tofacitinib affects normalization of endothelial vessel 471 organization(83), decreases tumor interstitial pressure due to reduction in inflammation, or reduces 472 matrix proteins that can inhibit therapeutic antibody penetration(84). However, as tofacitinib is 473 approved for treatment of fibrosis and significantly decreases deposition of ECM proteins, especially 474 collagens(85), this may be an additional benefit of using this specific compound. By microscopy, 475 some tofacitinib-mediated reductions in fibrosis within our tumor models was noted, but this was 476 not quantified. Further, when monitoring anti-tumor effects, possible contributions from reduced 477 levels of cytokines promoting tumor survival or proliferation cannot be excluded. Future studies will 478 focus on these important issues.
479
Of additional interest, CD11b + populations are inversely correlated with the effectiveness of 480 checkpoint inhibitor treatments (86, 87) . A potential role for tofacitinib in this setting is especially 481 intriguing, as not only does tofacitinib deplete tumor-associated CD11b + populations, but also 482 suppresses transcription of PD-L1 through a STAT-dependent mechanism(88). As shown in Table   483 1, we observed a decrease in transcript levels of PD-L1 in the tumors of tofacitinib-treated mice. In 484 conjunction with the observed improvement in tumor access for antibody based therapeutics, we 485 speculate that these unique effects could result in tofacitinib enhancement of checkpoint-based 486 immunotherapy agents in poorly responsive cancers, including pancreatic cancers. However, it is 487 unclear how tofacitinib might affect T-cell populations required for effective tumor clearance upon 488 checkpoint blockade.
489
In summary, our data show that tofacitinib, a FDA approved small molecule JAK/STAT 490 inhibitor with an acceptable safety profile in humans, alters the tumor microenvironment through 491 suppression of the chemokines that attract inflammatory cells. Broadly, our data suggest that 492 depletion of tumor-associated inflammatory cells through inhibition of chemokine signaling may 493 improve the treatment efficacy of antibody-based anti-cancer therapeutics and suggests that 494 tofacitinib or similar anti-inflammatory drugs could be used in combination with antibody-based 100mm 3 , mice were randomized into treatment groups (n=6-8 mice per group) and treated with 515 vehicle alone, tofacitinib (2 x 5mg/kg), HB21-PE40 (0.1mg/kg) or LMB-100 (2.5mg/kg), or the 516 combination of tofactinib and immunotoxin. Mice were treated every other day for one (MDA-MB-517 468) or two (KLM-1) treatment cycles with four injections per cycle. Tofacitinib was dissolved in 518 30% PEG300/5% Tween80/PBS and injected IP once in the morning with the second injection 8 519 hours later to mimic the twice daily human dosing schedules. Immunotoxin injections were 520 performed every other day via tail vein for each mouse in conjunction with the second daily 521 tofactinib dosing. Anetumab ravtansine (kindly provided by Bayer AG; Leverkusen, Germany) was 522 diluted in the supplied vehicle (10mM histidine, 130mM glycine, 5% sucrose in water). Each 523 treatment cycle consisted of 3x10mg/kg tofacitinib and 1x10mg/kg anetumab ravtansine with mice 524 treated once per day with tofacitinib and anetumab ravtansine delivered via tail vein concurrent with 525 the 3 rd dose. Tumor volume and animal weight were measured at least three times weekly. Tumor 526 volume was calculated as 0.5*(l x w 2 ). Animals were euthanized by CO 2 inhalation once tumors NSolver software (Nanostring Technologies), with differential expression compared by pooled 543 cluster analysis. Transcript differences between vehicle and tofacitinib-treated RNA pools were 544 ordered according to the magnitude of fold-change and transcripts with >2-fold changes were Immunotoxins or antibodies were labeled with the AlexaFluor-647 Protein Labeling Kit 575 (ThermoFisher Scientific). Labeled proteins were purified on PD-10 desalting columns (GE Life 576 Sciences) and concentrations determined by spectrophotometry. Dye:protein ratio was measured 577 according to manufacturer instructions and was within manufacturer-specified optimal range. To 578 ensure that the fluorescent labeling process did not interfere with immunotoxin activity, in vitro cell 579 killing assays were performed comparing labeled and unlabeled immunotoxin. Less than 1-log 580 reduction in cell killing was noted between the two preparations at equivalent concentrations, 581 indicating that the labeled immunotoxin was still capable of binding and internalization. Arginase-1 quantification 602 Protocol adapted from Corraliza, et al(56) . Equal volumes of tumor supernatant and assay buffer 603 (10mM MnCl 2 , 50 mM Tris-HCl, pH 7.5) were mixed and placed at 55°C for 10 minutes to activate 604 the enzyme. Arginine hydrolysis was initiated by the addition of 0.5M arginine to the lysate and 605 incubation at 37°C for 60 minutes. The reaction was quenched with the addition of a 1:3:7 mixture 606 of sulfuric acid, phosphoric acid, and water. 9% ISPF dissolved in ethanol was added to the 607 quenched reaction and incubated at 100°C for 45 minutes. Urea concentration was determined by 608 measuring OD540. Two-fold dilutions of urea (0.75-30μg) were used to generate a standard curve.
609
One unit of enzyme activity was defined as the amount of arginase that catalyzes the formation of 610 1μg urea in 60 minutes. (n=5-6 mice per treatment group). Mice received three cycles of treatment with a week between 954 cycles (arrows). Tumor volumes were measured and significance was calculated by unpaired two-955 tailed t-test between each treatment group at experimental endpoints; **p<0.01 , *** p<0.001. . For 956 KLM-1 tumors, a preliminary experiment with only one cycle of treatment at a lower ADC dose 957 showed enhancement of ADC activity with tofacitinib compared to ADC alone, but of a lower 958 magnitude ( Supplemental Fig 4) . C. Kaplan-Meyer plot displaying time-to-death of each treatment 959 group for mice implanted with KLM-1 tumors. Log-rank test was performed to calculate 960 significance between anetumab ravtansine alone and anetumab ravtansine +tofacitinib treatments. * 
